Regenxbio (RGNX) Current Deferred Revenue (2014 - 2026)

Regenxbio's Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $29.4 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 25465.22% year-over-year to $29.4 million; the TTM figure through Dec 2025 stood at $29.4 million (up 25465.22% YoY), while the FY2025 annual figure was $29.4 million, up 25465.22% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $29.4 million, up from $13.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $39.9 million in Q1 2025, with the low at $13000.0 in Q1 2024.
• The 5-year median for Current Deferred Revenue is $3.3 million (2021), against an average of $7.8 million.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue slumped 99.01% in 2024, then jumped 306707.69% in 2025.
• Regenxbio's Current Deferred Revenue stood at $3.3 million in 2021, then plunged by 45.12% to $1.8 million in 2022, then tumbled by 91.91% to $148000.0 in 2023, then dropped by 22.3% to $115000.0 in 2024, then jumped by 25465.22% to $29.4 million in 2025.
• Business Quant data shows RGNX's Current Deferred Revenue at $29.4 million in Q4 2025, $13.2 million in Q3 2025, and $37.8 million in Q2 2025.